Regent Pacific Group（RPGL.F）株式概要リージェント・パシフィック・グループ・リミテッドは投資持株会社で、欧州、米国、アジア太平洋地域のヘルスケアおよびライフサイエンス部門に投資している。 詳細RPGL.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析マイナスの株主資本 株式の流動性は非常に低い 収益が 100 万ドル未満 ( $363K )意味のある時価総額がありません ( $25M )+1 さらなるリスクすべてのリスクチェックを見るRPGL.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.00597.3k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-66m6m2016201920222025202620282031Revenue US$10.8kEarnings US$1.6kAdvancedSet Fair ValueView all narrativesRegent Pacific Group Limited 競合他社LipocineSymbol: NasdaqCM:LPCNMarket cap: US$17.8mVYNE TherapeuticsSymbol: NasdaqCM:VYNEMarket cap: US$22.6mIGC PharmaSymbol: NYSEAM:IGCMarket cap: US$28.5mMariMedSymbol: OTCPK:MRMDMarket cap: US$29.9m価格と性能株価の高値、安値、推移の概要Regent Pacific Group過去の株価現在の株価HK$0.005952週高値HK$0.4352週安値HK$0.0007ベータ1.191ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化-92.98%5年間の変化-98.91%IPOからの変化-97.54%最新ニュースお知らせ • May 07Regent Pacific Group Limited, Annual General Meeting, May 29, 2026Regent Pacific Group Limited, Annual General Meeting, May 29, 2026, at 15:00 China Standard Time. Location: room 302, 3/f, first commercial building, 33-35 leighton road, causeway bay, Hong Kongお知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026お知らせ • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025お知らせ • Jun 30Regent Pacific Group Limited Announces Change in Composition of the Nomination CommitteeRegent Pacific Group Limited announced that Mrs. Jayne Sutcliffe, a Non-Executive Director, and Mr. Ihsan Al Chalabi, an Independent Non-Executive Director, have been appointed as a member of the nomination committee of the Company (the "Nomination Committee") with effect from 30 June 2025. Following the above changes, the composition of the Nomination Committee comprises five members, namely James Mellon (Chairman of the Nomination Committee), Jayne Sutcliffe, Mark Searle, Adrian Chan and Ihsan Al Chalabi.お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025, at 15:00 China Standard Time. Location: 14/f, fairmont house, 8 cotton tree drive, central, Hong Kongお知らせ • Mar 17Regent Pacific Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Regent Pacific Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025最新情報をもっと見るRecent updatesお知らせ • May 07Regent Pacific Group Limited, Annual General Meeting, May 29, 2026Regent Pacific Group Limited, Annual General Meeting, May 29, 2026, at 15:00 China Standard Time. Location: room 302, 3/f, first commercial building, 33-35 leighton road, causeway bay, Hong Kongお知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026お知らせ • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025お知らせ • Jun 30Regent Pacific Group Limited Announces Change in Composition of the Nomination CommitteeRegent Pacific Group Limited announced that Mrs. Jayne Sutcliffe, a Non-Executive Director, and Mr. Ihsan Al Chalabi, an Independent Non-Executive Director, have been appointed as a member of the nomination committee of the Company (the "Nomination Committee") with effect from 30 June 2025. Following the above changes, the composition of the Nomination Committee comprises five members, namely James Mellon (Chairman of the Nomination Committee), Jayne Sutcliffe, Mark Searle, Adrian Chan and Ihsan Al Chalabi.お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025, at 15:00 China Standard Time. Location: 14/f, fairmont house, 8 cotton tree drive, central, Hong Kongお知らせ • Mar 17Regent Pacific Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Regent Pacific Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025お知らせ • Dec 19Regent Pacific Group Limited Announces Submission of Senstend New Drug Application to the National Medical Products Administration in ChinaThe Board announced that commercial strategic partner Jiang Su Wan Bang Sheng Hua Yi Yao Ji Tuan You Xian Ze Ren Gong Si (Jiangsu Wanbang Biopharmaceutical Group Co. Ltd.) ("Wanbang Biopharmaceutical", a wholly-controlled company of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. ("Fosun")) has submitted the New Drug Application ("NDA") registration dossier with the National Medical Products Administration ("NMPA") on 17 December 2024, with approval expected within 12 months from the submission date. Wanbang Biopharmaceutical is responsible, at its own expense, for obtaining the NDA from NMPA and maintaining any and all regulatory approvals required for the importation of Senstend in the People's Republic of China ("China" or "PRC"). In addition, and importantly, Wanbang Biopharmaceutical has signed an exclusive manufacturing and supply agreement with, inter alia, Genetic S.p. A. ("Genetic") and Jiang Su Wan Bang Yi Yao Ying Xiao You Xian Gong Si (Wanbang Pharmaceutical Marketing and Distribution Co. Ltd) ("Wanbang MKT", an affiliate of Wanbang Biopharmaceutical) on 26 August 2024, where Genetic will manufacture and supply Senstend to Wanbang Biopharmaceutical based on purchase orders received from Wanbang Biopharmaceutical. As previously mentioned, on the NDA being approved by NMPA, USD 5 million (or approximately HKD 39 million) and on first commercial launch USD 2 million (or approximately HKD 15.60 million) will be payable to the Group from Wanbang Biopharm pharmaceutical.お知らせ • Aug 16Regent Pacific Group Limited to Report First Half, 2024 Results on Aug 28, 2024Regent Pacific Group Limited announced that they will report first half, 2024 results on Aug 28, 2024お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, May 30, 2024Regent Pacific Group Limited, Annual General Meeting, May 30, 2024, at 15:00 China Standard Time. Location: 14/F, Fairmont House, 8 Cotton Tree Drive, Central Hong Kong Agenda: To receive, consider and adopt the audited financial statements of the Company and the reports of the Directors and the independent auditor of the Company for the year ended 31 December 2023; to re-appoint RSM Hong Kong as the independent auditor of the Company and to authorise the Board to fix their remuneration; to re-elect the following Directors, each as a separate ordinary resolution, and to authorise the Board to fix the remuneration of the Directors for the year ending 31 December 2024; and to consider other matters.お知らせ • Mar 26Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million.Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million on March 24, 2024. The consideration consists of CNY 8 million in cash. As part of the consideration, CNY 8 million was paid towards common equity. . West China Coking & Gas Company Limited reported the unaudited net loss of CNY 8.9 million as at 31 December 2023. The completion of the transaction is conditional upon all necessary corporate, governmental or regulatory approvals of the Disposal (the “Conditions”) including but not limited to unanimous approval from the shareholders of the Target Company and any relevant PRC governmental or regulatory bodies.お知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024Regent Pacific Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024お知らせ • Aug 18Regent Pacific Group Limited to Report First Half, 2023 Results on Aug 29, 2023Regent Pacific Group Limited announced that they will report first half, 2023 results on Aug 29, 2023お知らせ • Jul 23Regent Pacific Group Limited Provides Consolidated Earnings Guidance for the Period Ended 30 June 2023Regent Pacific Group Limited provided consolidated earnings guidance for the period ended 30 June 2023. The group expects to record a loss attributable to the equity holders of the company for the period ended 30 June 2023 (the "Reporting Period") of between approximately USD 12 million (or approximately HKD 93.60 million) to approximately USD 15 million (or approximately HKD 117 million), which represents a substantial decrease in the loss as compared to a loss attributable to the equity holders of the Company of approximately USD 20.06 million (or approximately HKD 156.47 million) for the period ended 30 June 2022 (the "Corresponding Period").お知らせ • Feb 18Endurance RP Limited Provides Earnings Guidance for the Year Ended 31 December 2022Endurance RP Limited provided earnings guidance for the year ended 31 December 2022. For the year, the Group expects to record a loss attributable to the equity holders of the Company of between approximately USD 33 million (or approximately HKD 257.40 million) to approximately USD 36 million (or approximately HKD 280.80 million), which represents a substantial increase in the loss as compared to the loss attributable to the equity holders of the Company of approximately USD12.60 million (or approximately HKD 98.28 million) for the year ended 31 December 2021 (the Corresponding Period).株主還元RPGL.FUS PharmaceuticalsUS 市場7D0%4.9%1.0%1Yn/a44.2%28.7%株主還元を見る業界別リターン: RPGL.FがUS Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: RPGL.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is RPGL.F's price volatile compared to industry and market?RPGL.F volatilityRPGL.F Average Weekly Movementn/aPharmaceuticals Industry Average Movement10.1%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: RPGL.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のRPGL.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト199116Jamie Alexander Gibsonwww.regentpac.comリージェント・パシフィック・グループ・リミテッドは投資持株会社で、欧州、米国、アジア太平洋地域のヘルスケア・ライフサイエンス分野に投資を行っている。同社はバイオファーマ部門と企業投資部門を通じて事業を展開している。泌尿器疾患の治療・管理用医薬品の研究・開発・製造・マーケティング・販売、分子・細胞・組織・臓器・システム・生理・心理レベルで老化速度を追跡する人工知能システムの開発などを手がけている。また、上場・非上場企業への投資も行っている。さらに、経営サービスも提供している。旧社名はエンデュランスRPリミテッドで、2023年7月にリージェント・パシフィック・グループ・リミテッドに社名変更した。リージェント・パシフィック・グループ・リミテッドは1991年に設立され、香港のセントラルに本社を置く。もっと見るRegent Pacific Group Limited 基礎のまとめRegent Pacific Group の収益と売上を時価総額と比較するとどうか。RPGL.F 基礎統計学時価総額US$24.58m収益（TTM）-US$4.71m売上高(TTM)US$363.00k67.7xP/Sレシオ-5.2xPER（株価収益率RPGL.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計RPGL.F 損益計算書（TTM）収益US$363.00k売上原価US$783.00k売上総利益-US$420.00kその他の費用US$4.29m収益-US$4.71m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.016グロス・マージン-115.70%純利益率-1,297.52%有利子負債／自己資本比率-54.6%RPGL.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 06:37終値2026/03/18 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Regent Pacific Group Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Keith RedpathCavendishSanjay JhaHybridan LLP
お知らせ • May 07Regent Pacific Group Limited, Annual General Meeting, May 29, 2026Regent Pacific Group Limited, Annual General Meeting, May 29, 2026, at 15:00 China Standard Time. Location: room 302, 3/f, first commercial building, 33-35 leighton road, causeway bay, Hong Kong
お知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026
お知らせ • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025
お知らせ • Jun 30Regent Pacific Group Limited Announces Change in Composition of the Nomination CommitteeRegent Pacific Group Limited announced that Mrs. Jayne Sutcliffe, a Non-Executive Director, and Mr. Ihsan Al Chalabi, an Independent Non-Executive Director, have been appointed as a member of the nomination committee of the Company (the "Nomination Committee") with effect from 30 June 2025. Following the above changes, the composition of the Nomination Committee comprises five members, namely James Mellon (Chairman of the Nomination Committee), Jayne Sutcliffe, Mark Searle, Adrian Chan and Ihsan Al Chalabi.
お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025, at 15:00 China Standard Time. Location: 14/f, fairmont house, 8 cotton tree drive, central, Hong Kong
お知らせ • Mar 17Regent Pacific Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Regent Pacific Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025
お知らせ • May 07Regent Pacific Group Limited, Annual General Meeting, May 29, 2026Regent Pacific Group Limited, Annual General Meeting, May 29, 2026, at 15:00 China Standard Time. Location: room 302, 3/f, first commercial building, 33-35 leighton road, causeway bay, Hong Kong
お知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026
お知らせ • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025
お知らせ • Jun 30Regent Pacific Group Limited Announces Change in Composition of the Nomination CommitteeRegent Pacific Group Limited announced that Mrs. Jayne Sutcliffe, a Non-Executive Director, and Mr. Ihsan Al Chalabi, an Independent Non-Executive Director, have been appointed as a member of the nomination committee of the Company (the "Nomination Committee") with effect from 30 June 2025. Following the above changes, the composition of the Nomination Committee comprises five members, namely James Mellon (Chairman of the Nomination Committee), Jayne Sutcliffe, Mark Searle, Adrian Chan and Ihsan Al Chalabi.
お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025, at 15:00 China Standard Time. Location: 14/f, fairmont house, 8 cotton tree drive, central, Hong Kong
お知らせ • Mar 17Regent Pacific Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Regent Pacific Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025
お知らせ • Dec 19Regent Pacific Group Limited Announces Submission of Senstend New Drug Application to the National Medical Products Administration in ChinaThe Board announced that commercial strategic partner Jiang Su Wan Bang Sheng Hua Yi Yao Ji Tuan You Xian Ze Ren Gong Si (Jiangsu Wanbang Biopharmaceutical Group Co. Ltd.) ("Wanbang Biopharmaceutical", a wholly-controlled company of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. ("Fosun")) has submitted the New Drug Application ("NDA") registration dossier with the National Medical Products Administration ("NMPA") on 17 December 2024, with approval expected within 12 months from the submission date. Wanbang Biopharmaceutical is responsible, at its own expense, for obtaining the NDA from NMPA and maintaining any and all regulatory approvals required for the importation of Senstend in the People's Republic of China ("China" or "PRC"). In addition, and importantly, Wanbang Biopharmaceutical has signed an exclusive manufacturing and supply agreement with, inter alia, Genetic S.p. A. ("Genetic") and Jiang Su Wan Bang Yi Yao Ying Xiao You Xian Gong Si (Wanbang Pharmaceutical Marketing and Distribution Co. Ltd) ("Wanbang MKT", an affiliate of Wanbang Biopharmaceutical) on 26 August 2024, where Genetic will manufacture and supply Senstend to Wanbang Biopharmaceutical based on purchase orders received from Wanbang Biopharmaceutical. As previously mentioned, on the NDA being approved by NMPA, USD 5 million (or approximately HKD 39 million) and on first commercial launch USD 2 million (or approximately HKD 15.60 million) will be payable to the Group from Wanbang Biopharm pharmaceutical.
お知らせ • Aug 16Regent Pacific Group Limited to Report First Half, 2024 Results on Aug 28, 2024Regent Pacific Group Limited announced that they will report first half, 2024 results on Aug 28, 2024
お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, May 30, 2024Regent Pacific Group Limited, Annual General Meeting, May 30, 2024, at 15:00 China Standard Time. Location: 14/F, Fairmont House, 8 Cotton Tree Drive, Central Hong Kong Agenda: To receive, consider and adopt the audited financial statements of the Company and the reports of the Directors and the independent auditor of the Company for the year ended 31 December 2023; to re-appoint RSM Hong Kong as the independent auditor of the Company and to authorise the Board to fix their remuneration; to re-elect the following Directors, each as a separate ordinary resolution, and to authorise the Board to fix the remuneration of the Directors for the year ending 31 December 2024; and to consider other matters.
お知らせ • Mar 26Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million.Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million on March 24, 2024. The consideration consists of CNY 8 million in cash. As part of the consideration, CNY 8 million was paid towards common equity. . West China Coking & Gas Company Limited reported the unaudited net loss of CNY 8.9 million as at 31 December 2023. The completion of the transaction is conditional upon all necessary corporate, governmental or regulatory approvals of the Disposal (the “Conditions”) including but not limited to unanimous approval from the shareholders of the Target Company and any relevant PRC governmental or regulatory bodies.
お知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024Regent Pacific Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024
お知らせ • Aug 18Regent Pacific Group Limited to Report First Half, 2023 Results on Aug 29, 2023Regent Pacific Group Limited announced that they will report first half, 2023 results on Aug 29, 2023
お知らせ • Jul 23Regent Pacific Group Limited Provides Consolidated Earnings Guidance for the Period Ended 30 June 2023Regent Pacific Group Limited provided consolidated earnings guidance for the period ended 30 June 2023. The group expects to record a loss attributable to the equity holders of the company for the period ended 30 June 2023 (the "Reporting Period") of between approximately USD 12 million (or approximately HKD 93.60 million) to approximately USD 15 million (or approximately HKD 117 million), which represents a substantial decrease in the loss as compared to a loss attributable to the equity holders of the Company of approximately USD 20.06 million (or approximately HKD 156.47 million) for the period ended 30 June 2022 (the "Corresponding Period").
お知らせ • Feb 18Endurance RP Limited Provides Earnings Guidance for the Year Ended 31 December 2022Endurance RP Limited provided earnings guidance for the year ended 31 December 2022. For the year, the Group expects to record a loss attributable to the equity holders of the Company of between approximately USD 33 million (or approximately HKD 257.40 million) to approximately USD 36 million (or approximately HKD 280.80 million), which represents a substantial increase in the loss as compared to the loss attributable to the equity holders of the Company of approximately USD12.60 million (or approximately HKD 98.28 million) for the year ended 31 December 2021 (the Corresponding Period).
